Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Gains from Sales and Divestitures (2022 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $36417.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures fell 3.68% year-over-year to $36417.0, compared with a TTM value of $36417.0 through Dec 2025, down 3.68%, and an annual FY2025 reading of $397900.0, up 47.19% over the prior year.
  • Gains from Sales and Divestitures was $36417.0 for Q4 2025 at Neuroone Medical Technologies, down from $397900.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $397900.0 in Q3 2025 and bottomed at $32535.0 in Q1 2024.
  • Average Gains from Sales and Divestitures over 4 years is $169669.7, with a median of $136573.5 recorded in 2022.
  • Peak annual rise in Gains from Sales and Divestitures hit 786.88% in 2025, while the deepest fall reached 84.62% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $40624.0 in 2022, then decreased by 7.25% to $37679.0 in 2023, then increased by 0.35% to $37809.0 in 2024, then dropped by 3.68% to $36417.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for NMTC at $36417.0 in Q4 2025, $397900.0 in Q3 2025, and $35771.0 in Q2 2025.